288 related articles for article (PubMed ID: 35609385)
1. Current state of CFTR modulators for treatment of Cystic Fibrosis.
Despotes KA; Donaldson SH
Curr Opin Pharmacol; 2022 Aug; 65():102239. PubMed ID: 35609385
[TBL] [Abstract][Full Text] [Related]
2. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
3. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ
Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995
[TBL] [Abstract][Full Text] [Related]
4. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
[TBL] [Abstract][Full Text] [Related]
5. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
Mayer-Hamblett N; Boyle M; VanDevanter D
Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
[TBL] [Abstract][Full Text] [Related]
6. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis.
Sergeev V; Chou FY; Lam GY; Hamilton CM; Wilcox PG; Quon BS
Ann Am Thorac Soc; 2020 Feb; 17(2):147-154. PubMed ID: 31661636
[TBL] [Abstract][Full Text] [Related]
7. Cystic fibrosis: candidate selection and impact of the cystic fibrosis transmembrane conductance regulator therapy.
Lehr CJ; Pilewski JM
Curr Opin Organ Transplant; 2022 Jun; 27(3):198-203. PubMed ID: 35184094
[TBL] [Abstract][Full Text] [Related]
8. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
Cuyx S; De Boeck K
Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic pipeline for individuals with cystic fibrosis with mutations nonresponsive to current cystic fibrosis transmembrane conductance regulator modulators.
Fajac I; Sermet-Gaudelus I
Curr Opin Pulm Med; 2021 Nov; 27(6):567-574. PubMed ID: 34494979
[TBL] [Abstract][Full Text] [Related]
10. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
11. CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France.
Regard L; Martin C; Burnet E; Da Silva J; Burgel PR
Cells; 2022 May; 11(11):. PubMed ID: 35681464
[TBL] [Abstract][Full Text] [Related]
12. One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies.
Ensinck MM; Carlon MS
Cells; 2022 Jun; 11(12):. PubMed ID: 35740997
[TBL] [Abstract][Full Text] [Related]
13. An update on new and emerging therapies for cystic fibrosis.
Hudock KM; Clancy JP
Expert Opin Emerg Drugs; 2017 Dec; 22(4):331-346. PubMed ID: 29264936
[TBL] [Abstract][Full Text] [Related]
14. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
15. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.
Lee TW; Southern KW; Perry LA; Penny-Dimri JC; Aslam AA
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD005599. PubMed ID: 27314455
[TBL] [Abstract][Full Text] [Related]
16. New Therapies to Correct the Cystic Fibrosis Basic Defect.
Bergeron C; Cantin AM
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34201249
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of cystic fibrosis treatment.
Carter SC; McKone EF
Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule drugs for cystic fibrosis: Where are we now?
Laselva O; Guerra L; Castellani S; Favia M; Di Gioia S; Conese M
Pulm Pharmacol Ther; 2022 Feb; 72():102098. PubMed ID: 34793977
[TBL] [Abstract][Full Text] [Related]
19. Towards next generation therapies for cystic fibrosis: Folding, function and pharmacology of CFTR.
Bose SJ; Krainer G; Ng DRS; Schenkel M; Shishido H; Yoon JS; Haggie PM; Schlierf M; Sheppard DN; Skach WR
J Cyst Fibros; 2020 Mar; 19 Suppl 1(Suppl 1):S25-S32. PubMed ID: 31902693
[TBL] [Abstract][Full Text] [Related]
20. Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis.
Southern KW; Castellani C; Lammertyn E; Smyth A; VanDevanter D; van Koningsbruggen-Rietschel S; Barben J; Bevan A; Brokaar E; Collins S; Connett GJ; Daniels TWV; Davies J; Declercq D; Gartner S; Gramegna A; Hamilton N; Hauser J; Kashirskaya N; Kessler L; Lowdon J; Makukh H; Martin C; Morrison L; Nazareth D; Noordhoek J; O'Neill C; Owen E; Oxley H; Raraigh KS; Raynal C; Robinson K; Roehmel J; Schwarz C; Sermet I; Shteinberg M; Sinha I; Takawira C; van Mourik P; Verkleij M; Waller MD; Duff A
J Cyst Fibros; 2023 Jan; 22(1):17-30. PubMed ID: 36916675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
